Nudging for Anticoagulation Adherence in Atrial Fibrillation
- Sponsor
- Sun Yat-sen University
- Study ID
- NCT07543393
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Atrial Fibrillation (AF)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nudge Intervention — BEHAVIORALParticipants receive a multi-component nudge intervention including: an educational video on atrial fibrillation and stroke prevention; a personalized action plan linking pill-taking to a daily routine; a paper medication calendar with check-off grid and visual cues; tapered SMS reminders (weekly frequency declines from 3 to 1 over 8 weeks); weekly feedback messages; and a mid-point telephone call at week 4.
Study Details
The goal of this clinical trial is to learn if a nudging intervention (using text message reminders, a medication calendar, and action planning) can help people with atrial fibrillation take their blood-thinning medication (anticoagulants) as prescribed. The main questions it aims to answer are: Does the nudging intervention improve medication adherence compared to usual care? How does the intervention affect patients' beliefs about their medication and the automaticity of pill-taking? Is the intervention cost-effective? Researchers will compare participants who receive the nudging intervention with those who receive usual care. Participants will: Watch a short educational video about atrial fibrillation and stroke prevention Make a personal plan to take their medication at the same time each day (for example, after breakfast) Receive text message reminders 1 to 3 times per week, with fewer messages over time Get a medication calendar to track daily doses Answer a few questionnaires at the start, at 8 weeks, and at 12 weeks
Key Dates
- First listed
- Apr 21, 2026
- Start date
- Jun 30, 2026
- Status verified
- Jun 2026
- Primary completion
- Feb 20, 2027
- Completion
- Feb 20, 2027
Study Design
- Enrollment
- 84 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Nudge InterventionParticipants receive a multi-component nudge intervention including: an educational video on atrial fibrillation and stroke prevention; a personalized action plan linking pill-taking to a daily routine (e.g., after breakfast); a paper medication calendar with check-off grid and visual cues; tapered SMS reminders (3 times/week for weeks 1-3, 2 times/week for weeks 4-6, 1 time/week for weeks 7-8); weekly feedback messages on Sundays; and a mid-point telephone call at week 4 to address barriers and adjust the plan.
- No Intervention: Usual CareParticipants receive usual care as routinely provided by the cardiology clinic, including standard discharge education and regular follow-up visits. No additional adherence support is given during the study period. After the study is completed, participants in this arm will be offered the same medication calendar and text message templates as the intervention group.
Primary Outcome Measure
Medication Adherence measured by the Medication Adherence Estimation and Differentiation Scale (MEDS) [ Time Frame: Baseline (week 0), end of intervention (week 8), and follow-up (week 12) ]
Central Contacts
- Zhaokang Wan, RN, MSN candidate+8615919327731
Related Studies
- Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.Recruiting · Cardiovascular Innovation and Research Institute · Glenwood Springs, Colorado
- KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial FibrillationEnrolling By Invitation · Northwestern University · Chicago, Illinois
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)PHASE3 · Recruiting · Anthos Therapeutics, Inc. · Birmingham, Alabama
- Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial FibrillationEARLY_PHASE1 · Recruiting · China National Center for Cardiovascular Diseases · Boston, Massachusetts